VJHemOnc Podcast
VJHemOnc
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
Mentioned books
Sep 14, 2020 • 16min
Latest AML therapies: novel preparations and first in class agents
Guests Thomas Cluzeau, Naval Daver, and Andrew Wei discuss the latest AML therapies, including the use of CPX351 as a potential cure for certain patients, the safety and efficacy of Magrola MAB in combination with azacitidine, the high response rates and safety profile of treatment for TP53 AML patients, and updates on Venetoclax plus low dose Cytarabine study in previously untreated older AML patients.
Sep 10, 2020 • 11min
Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells
This podcast discusses advances in the lymphoma field, including targeted therapies, PET-guided omission of radiotherapy, and CAR T-cell therapy. Updates on diffused large B-cell lymphoma and Hodgkin's lymphoma are highlighted, along with findings from a phase 2 study on axi-captaging silo-lucil in relapse refractory lymphomas.
Aug 13, 2020 • 13min
CLL: MRD and first-in class agents
CLL treatment developments and the use of minimal residual disease (MRD) in disease monitoring are discussed. Topics include achieving undetectable MRD with Venetoclax and ebrutinib, updated efficacy and safety results of Venetoclax versus Venetuzumab and Clorambacil in previously untreated patients, and combining Brutinib and Venetoclax for CLL and small lymphocytic lymphoma.
Aug 6, 2020 • 52min
The Myeloma Sessions: Evolving management of myeloma & COVID-19
María-Victoria Mateos discusses evolving management of myeloma & COVID-19, including reducing infection risk, mortality rates of myeloma patients, immunity and thrombogenic potential of COVID-19, managing myeloma patients, repurposing myeloma drugs for COVID-19 treatment, and advancements in CAR-T and bi-specific therapies for multiple myeloma.
Aug 6, 2020 • 12min
MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls
The podcast features Srdan Verstovsek discussing key updates in the treatment and management of MPNs. They delve into the combination of Roxolytinev and CPI 610, explore the use of nebulae clacks in myelor fibrosis patients, and highlight the efficacy and tolerability of combination treatment. They also discuss novel therapy approaches, clinical trials targeting therapy beyond jack inhibition, and the importance of transplantation as a potential therapy.
Jul 31, 2020 • 44min
The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies
Experts Barbara Eichhorst, Susan O’Brien, and Matthew Davids discuss frontline therapy, BTK inhibitors, MRD negativity, novel therapies, CLL14 trial updates, debulking strategies, achieving MRD negativity, triple combination therapies, sequencing in CLL treatment, non-covalent BTK inhibitors, and ongoing studies in CLL treatment.
Jul 28, 2020 • 57min
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
Experts discuss treating hematologic malignancies during the COVID-19 pandemic, reducing nosocomial COVID-19 infections, clinical trial participation, and resource allocation. They highlight challenges in patient management, resource distribution, and the use of telemedicine. The impact on clinical trials, treatment considerations, and the need for international collaboration are also discussed.
Jul 16, 2020 • 53min
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
Marion Subklewe, Amir Fathi, and Andrew Wei discuss emerging immunotherapies, venetoclax-based regimens, and targeted therapies in AML. They explore challenges in translating successful treatment strategies, discuss treatment options and challenges for TP53 mutated AML patients, and highlight the importance of targeted therapies. The speakers also delve into designing frontline phase three studies for older AML patients and the challenges of label expansion for emerging immunotherapies.
Jul 7, 2020 • 16min
Key updates in ALL at EHA 2020
Researchers from Spain, the US, and Austria discuss key updates in acute lymphoblastic leukemia (ALL) at EHA 2020 congress, including the role of the gut microbiome in disease development, modulation of the gut microbiome for prevention, efficacy and toxicity of novel agents in ALL treatment, and the use of total body irradiation in children and adolescents with ALL.
Jul 3, 2020 • 46min
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
Francesca Gay, an expert in multiple myeloma, discusses the latest developments in the field. Topics include high-risk smoldering myeloma, monoclonal antibody treatment, MRD monitoring, T cell engagers and CAR T cells in immunotherapy, and the advantages and limitations of CAR-T cell therapy and bi-specific antibodies.
